Former Editor of The Economist joins Airfinity as advisor

Posted on Jan 17, 2023

Airfinity is pleased to welcome Bill Emmott, the longest serving Editor of The Economist in modern times, to its advisory board as part of the company’s increased investment into serving media worldwide with health data and information.

Bill currently holds a number of leadership roles including co-Director of the Global Commission for Post-Pandemic Policy and Chair of the International Institute for Strategic Studies.

Bill Emmott says: “Airfinity has done groundbreaking work on COVID-19 and all its implications, and become an indispensable part of the global health information infrastructure; it’s possibly the most quoted health data company in the world. I welcome the opportunity to help the team expand and develop its health risk data offering. The world faces unprecedented natural challenges and can only meet these with the right data.”

Rasmus Bech Hansen, Airfinity’s founder and CEO says: “The pandemic has proven to us all that accurate data and information is critical to responding to global health threats in time and that these tools can save lives. But this area is also more challenged than ever by misinformation campaigns, increased politicization of health matters and reduced investment in health journalism.

We have seen the need for our unbiased, fact driven analytics grow enormously. I am excited to welcome someone with Bill’s enormous experience in global affairs to the company as an advisor. I look forward to working with him on strengthening our biorisk assessment capabilities and more broadly our efforts to inform the public on key global health related matters.”

View our full leadership team and advisory board here.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022